Auryxia (Ferric Citrate) Patent Expiration, LOE Window & CMS Spending

Auryxia (Ferric Citrate) by Keryx Biopharmaceuticals: FDA Orange Book LOE 2030-07-21, 1 AB generics, $147.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKeryx Biopharmaceuticals
FDA Application & PathwayN205874 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-07-21
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$147.1M
2024 Medicare Part D Spend$131.5M
2024 Medicaid Spend$15.6M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 22.7% 2-yr change)